banner
Home / News / Cannabis Conference to Feature Home Grow, Medical Cannabis Research Education
News

Cannabis Conference to Feature Home Grow, Medical Cannabis Research Education

Jun 11, 2023Jun 11, 2023

For the past seven years, Cannabis Conference, produced by Cannabis Business Times, has become known for its high-level education exclusively geared toward plant-touching businesses.

The 2023 Cannabis Conference—happening Aug. 15-17 at the Paris Las Vegas Hotel & Casino—will include some of the best programming to date. This year, the Cannabis Conference education program will feature groundbreaking sessions that will dive into the realms of home cultivation and the cutting edge of medical cannabis research.

As more and more states allow home cannabis cultivation for medical patients and/or adult-use consumers, the demand for information on starting and succeeding with a home grow is at an all-time high. Cannabis Conference will cover this burgeoning area of the industry in the following home grow sessions:

Tips and Tricks for Home Grow Design and Equipment (And Other Essentials)You’d like to begin growing at home, but you’re unsure where to begin ... While the B2B market has plenty of guidance for large-scale licensed cultivation businesses, the intricacies of growing cannabis at home will prompt plenty of questions—especially when it comes to controlling costs throughout the process. Scott Reach will cover everything you need to know from selecting equipment and genetics to temperature controls, airflow and more.

Kerry Bennett

Small-Scale Environmental Control: What Home Growers Need to Know to Stabilize Humidity and Temperature in Order to Maintain Healthy Plants and Maximize Yields

In this session, attendees will learn how to set up a retrofitted space that accounts for temperature control, relative humidity and other environmental elements, both during lights on and lights off, with accuracy and efficiency.

Because of cannabis’s Schedule 1 status as a federally controlled drug, medical cannabis research has faced significant limitations and restrictions. Nonetheless, certain companies have made progress developing formulations to address various conditions such as chronic pain, Parkinson’s disease and pulmonary inflammation. Companies are also working diligently toward the U.S. Food and Drug Administration-approved human trials, aiming to make cannabis-based treatments accessible to patients.

At Cannabis Conference, leaders in cannabis biopharmaceutical development will share their latest work in medical cannabis research in the following sessions:

Session: New Research Supports Cannabinoid-Based Treatments for Parkinson's Disease, Chronic Pain, Inflammation, and More

Cannabis medical research has long been limited and more difficult to perform because of its federally illegal status. GB Sciences, a plant-based research and biopharmaceutical drug development company, has been working to change that by getting FDA approval for human trials on prescription drug formulations to treat specific ailments. Dr. Andrea Small-Howard says this work is an important step in demonstrating medical value, which helps with the destigmatization of cannabis. She will discuss the company’s journey and latest research validating the efficacy of different cannabinoid-containing formulations designed for the treatment of Parkinson's disease, chronic pain, and inflammation.

Session: The Path To Prescription: One Company's Journey To Bring A Cannabinoid-Based Treatment To MarketCannabinoids biopharma company RS BioTherapeutics Inc. has formulated a first-in-class alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation, including chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS), pneumonia, and cystic fibrosis. Dr. Michelle L. Shuffett will share the company's journey to developing its novel cannabinoid-based treatment, RSBT-001, including what inspired the company to explore anti-inflammatory properties of cannabinoids, what makes the patent-pending formulation unique, steps required to get animal and human trials approved, what the findings have shown so far, and the timeline and costs expected to finally deliver the prescription to patients, and much more.

*The medical cannabis research and home grow sessions are accessible to all Cannabis Conference attendees with any pass type, including expo only.

Here are some of the other highly anticipated topics in the 2023 education program:

You can view the full agenda here.

Home Grow Sessions: What to KnowTips and Tricks for Home Grow Design and Equipment (And Other Essentials)The Top Mistakes for Home Growers to Avoid Small-Scale Environmental Control: What Home Growers Need to Know to Stabilize Humidity and Temperature in Order to Maintain Healthy Plants and Maximize Yields Session: New Research Supports Cannabinoid-Based Treatments for Parkinson's Disease, Chronic Pain, Inflammation, and MoreSession: The Path To Prescription: One Company's Journey To Bring A Cannabinoid-Based Treatment To Market